---
title: "The Smartest Growth Stock to Buy With $500 Right Now"
description: "Vertex isn't your run-of-the-mill biotech stock."
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/260265919.md"
published_at: "2025-10-08T10:07:16.000Z"
---

# The Smartest Growth Stock to Buy With $500 Right Now

> Vertex isn't your run-of-the-mill biotech stock.

Vertex isn't your run-of-the-mill biotech stock.

### Related Stocks

- [VRTX.US - Vertex Pharma](https://longbridge.com/en/quote/VRTX.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| Significant opportunities exist in the global pain market for novel mechanisms and modalities | The global pain market presents significant opportunities for innovation, particularly in developing non-addictive alter | [Link](https://longbridge.com/en/news/275921122.md) |
| Sionna Therapeutics Maps Mid-2026 CF Catalysts, Highlights NBD1 Stabilizers at Guggenheim Summit | Sionna Therapeutics presented its strategy for developing next-generation cystic fibrosis therapies focused on NBD1 stab | [Link](https://longbridge.com/en/news/276001201.md) |
| Newron Pharmaceuticals startet Phase-III-Studie mit Evenamide bei therapieresistenter Schizophrenie | Newron Pharmaceuticals S.p.A. has announced the release of clinical data on Evenamide, a novel glutamate modulator being | [Link](https://longbridge.com/en/news/274605134.md) |
| Health Canada Accepts Cipher Pharmaceuticals' Natroba Submission for Review | Cipher Pharmaceuticals Inc. announced that Health Canada has accepted its new drug submission for Natroba™ (Spinosad), a | [Link](https://longbridge.com/en/news/273997136.md) |
| How Is The Market Feeling About Vertex Pharmaceuticals Inc? | Vertex Pharmaceuticals Inc's short interest has decreased by 3.54%, with 4.29 million shares sold short, representing 1. | [Link](https://longbridge.com/en/news/272313190.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.